WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, November 20, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L4	(HPTP or protein adj3 tyrosine phosphatase) and crystal and x-ray and atomic coordinates	20
☐	L3	L2	0
	DB=USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L2	(HPTP or protein adj3 tyrosine phosphatase) and crystal and x-ray and atomic coordinates	5
☐	L1	HPTP pr protein adj3 tyrosine phosphatase	0

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 7037894 B2

L2: Entry 1 of 5 File: USPT May 2, 2006

US-PAT-NO: 7037894
DOCUMENT-IDENTIFIER: US 7037894 B2

TITLE: Stabilized proteins

DATE-ISSUED: May 2, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20020061549 A1	May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Marshall; Christopher P.	Brooklyn	NY		US
Hoffman; Alexander	Los Angeles	CA		US
Errico; Joseph P.	Far Hills	NJ		US
Marshall; Paul B.	Munich			DE

US-CL-CURRENT: 514/12; 424/130.1, 424/94.1, 424/94.3, 435/183, 435/198, 514/2, 530/350, 530/387.1, 530/388.21, 530/388.22, 530/388.24, 530/399

ABSTRACT:

Isolated polypeptides or polypeptide chains are modified by di-tyrosine cross-linking such that the retain at least one functional activity. In one embodiment, the isolated polypeptide or polypeptide chains comprise at least one di-tyrosine cross-link, wherein at least one tyrosine of the di-tyrosine cross-link originates from a point mutation to tyrosine, and wherein the di-tyrosine cross-linked protein retains at least one function displayed by the protein in the absence of di-tyrosine cross-linking. In another embodiment, the di-tyrosine cross-linked polypeptide or polypeptide chain has enhanced stability compared to the same polypeptide or polypeptide chain in the absence of di-tyrosine cross-linking. A method for stabilization of a polypeptide or polypeptide complex, by the introduction of intra-polypeptide and/or inter-polypeptide di-tyrosine bonds, which simultaneously maintains the structure and function of the polypeptide or polypeptide complex is also described.

25 Claims, 37 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 2. Document ID: US 6950757 B2

L2: Entry 2 of 5 File: USPT Sep 27, 2005

US-PAT-NO: 6950757
DOCUMENT-IDENTIFIER: US 6950757 B2

TITLE: Screening methods for identifying ligands

DATE-ISSUED: September 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stewart; Lansing J.	Bainbridge Island	WA		

US-CL-CURRENT: 702/27; 117/11, 435/6, 435/7.1

ABSTRACT:

This invention relates to crystallization based assays for identifying ligands that bind to a macromolecule.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 3. Document ID: US 6631332 B2

L2: Entry 3 of 5 File: USPT Oct 7, 2003

US-PAT-NO: 6631332
DOCUMENT-IDENTIFIER: US 6631332 B2

TITLE: Methods for using functional site descriptors and predicting protein function

DATE-ISSUED: October 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Jeffrey	San Diego	CA		
Fetrow; Jacquelyn S.	San Diego	CA		

US-CL-CURRENT: 702/19; 435/4, 436/86, 702/27

ABSTRACT:

The present invention concerns methods and systems for predicting the biological function(s) of proteins. The invention is based on the development of functional site descriptors for discrete protein biological functions. Functional site descriptors are geometric representations of protein functional sites in three-dimensional space, and can also include additional parameters, for example, conformational information. Following their development, one or more functional site descriptors (for one or more different biological functions) are used to probe protein structures to determine if such structures contain the functional sites described by the corresponding functional site descriptors. If so, the protein(s) containing the functional site(s) are predicted to have the corresponding biological function(s). In preferred embodiments, a library of functional site descriptors is used to probe inexact protein structures derived by computational methods from amino acid sequence information to predict the biological function(s) of such sequences and of the gene(s) encoding the same.

47 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 4. Document ID: WO 2004087905 A2

L2: Entry 4 of 5 File: DWPI Oct 14, 2004

DERWENT-ACC-NO: 2004-737704
DERWENT-WEEK: 200472

TITLE: Novel compound that interact with sulfenyl amide protein tyrosine phosphatases (PTP) to prevent or inhibit conversion of PTP sulfenyl amide to active form, useful for treating cancer, diabetes, rheumatoid arthritis and hypertension

INVENTOR: CARR, R A E; CONGREVE, M S ; JHOTI, H ; TISI, D J G ; VAN MONTFORT, R L M ; WALLIS, N G ; WILLIAMS, G

PRIORITY-DATA: 2003US-468543P (May 7, 2003), 2003US-459749P (April 2, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2004087905 A2	October 14, 2004	E	159	C12N009/16

INT-CL (IPC): C12N 9/16; G06F 17/50

ABSTRACTED-PUB-NO: WO2004087905A
BASIC-ABSTRACT:

NOVELTY - A compound (C1) that inhibits protein tyrosine phosphatases (PTP) by interacting with sulfenyl amide PTP to prevent or inhibit conversion of the PTP sulfenyl amide to an active form of PTP, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) isolated sulfenyl amide cysteine-containing protein (I), or its a homologue, allelic form, species variant, derivative or mutein;

(2) isolated protein sulfenyl amide (II) having HC(X5)R signature motif, or its a homologue, allelic form, species variant, derivative or mutein;

(3) isolated PTP sulfenyl amide (III), or its homologue, allelic form, species variant, derivative or mutein;

(4) screening (M1) for an inhibitor of a protein (such as PTP) capable of forming (I) to (III);

(5) producing (M2) an inhibitor of a protein (such as PTP) capable of forming (I) to (III);

(6) a protein (e.g., PTP) inhibitor (IV) obtained by any of the above methods;

(7) a pharmaceutical composition (V) containing (IV);

(8) use of a compound for the manufacture of a medicament for the treatment of a disease or condition mediated by PTP, where the compound is one that binds to PTP sulfenyl amide to prevent or inhibit conversion of the PTP sulfenyl amide to an active reduced form of the PTP;

(9) reducing (M3) the activity of PTP, the PTP being one which is convertible between an active form and an inactive form, the inactive form is in the presence of a sulfenyl amide moiety formed at the active site of the PTP;

(10) identifying (M4) by rational drug design a compound capable of reducing the level of activity of a (PTP) in a cellular environment;

(11) a crystal of sulfenyl amide protein tyrosine phosphatase 1B having a Unit cell dimensions: a = 87.686 Angstrom , b = 87.686 Angstrom , c=103.721 Angstrom , alpha =90.00 deg. , beta = 90.00 deg. , gamma = 120.00 deg. and a space group: P3(121) and a resolution better than that is numerically lower than 3.0 Angstrom and the structure defined by the coordinates (AC) of sulfenyl amide PTP1B as defined in patent specification plus or minus root mean square deviation from the C alpha atoms of not more than 1.5 Angstrom ;

(12) homology modeling (M5), by aligning a representation of an amino acid sequence of a target sulfenyl amide protein tyrosine phosphatase protein of unknown three-dimensional structure with the amino acid sequence of the sulfenyl amide protein tyrosine phosphatase 1B of (AC) to match homologous regions of the amino acid sequences, modeling the structure of the matched homologous regions of the target sulfenyl amide protein tyrosine phosphatase of unknown structure on the corresponding regions of the sulfenyl amide protein tyrosine phosphatase 1B structure as defined by (AC), and determining a conformation (e.g., so that favorable interactions are formed within the target sulfenyl amide protein tyrosine phosphatase of unknown structure and/or so that a low energy conformation is formed) for the target sulfenyl amide protein tyrosine phosphatase of unknown structure which substantially preserves the structure of the matched homologous regions;

(13) determining (M6) the structure of a protein, by providing (AC), and either positioning the co-ordinates in the crystal unit cell of the protein so as to provide a structure for the protein or assigning NMR spectra peaks of the protein by manipulating (AC);

(14) a system, particularly a computer system, containing either atomic coordinate data according to (AC) the data defining the three-dimensional structure of

sulfenyl amide protein tyrosine phosphatase 1B or its selected coordinates, structure factor data (where a structure factor comprises the amplitude and phase of the diffracted wave) for sulfenyl amide protein tyrosine phosphatase 1B, the structure factor data being derivable from (AC), atomic coordinate data of a target sulfenyl amide protein tyrosine phosphatase protein generated by homology of the target based on the data of (AC), atomic coordinate data of a target sulfenyl amide protein tyrosine phosphatase protein generated by interpreting X-ray crystallographic data or NMR data by reference to the data of (AC) or structure factor data derivable from the above two atomic coordinate data;

(15) a computer-readable storage medium, comprising a data storage material encoded with computer readable data, where the data are defined by all or a portion (e.g., selected coordinates as defined) of the structure coordinates of sulfenyl amide protein tyrosine phosphatase 1B of (AC), or a homologue of sulfenyl amide protein tyrosine phosphatase 1B, where the homologue comprises backbone atoms that have a root mean square deviation from the backbone atoms (nitrogen-carbon alpha -carbon) of (AC);

(16) computer readable media with at least one of atomic coordinate data of (AC);

(17) providing data for generating structures and/or performing rational drug design for sulfenyl amide PTP1B, its homologues or analogs, complexes of sulfenyl amide PTP1B or its homologues or analogs with candidate modulator;

(18) a computer based method of rational drug design;

(19) rational drug design, by providing the structure of the PTP1B sulfenyl amide as defined by (AC), providing the structure of a candidate compound, and fitting the structure of the candidate compound to the structure of the sulfenyl amide as defined by (AC);

(20) identifying by rational drug design a compound capable of reducing the level of activity of a protein tyrosine phosphatase (PTP) in a cellular environment;

(21) determining the structure of a compound bound to sulfenyl amide PTP1B;

(22) inhibiting or preventing the reduction of sulfenyl amide PTP1B to PTP1B in a cellular environment;

(23) a pharmaceutical composition (C2) comprising (C1) and an excipient;

(24) a three-dimensional representation of a PTP sulfenyl amide or its portion; and

(25) a computer based method for the analysis of the interaction of a molecular structure with a PTP sulfenyl amide.

ACTIVITY - Cytostatic; Antidiabetic; Antirheumatic; Antiarthritic; Hypotensive; Osteopathic; Anorectic; Immunosuppressive; Antiinflammatory.

MECHANISM OF ACTION - Inhibitor of conversion of PTP sulfenyl amide to an active reduced form of PTP.

No supporting data is given.

USE - (C1) is useful in medicine, e.g., for use in treatment of diseases or conditions mediated by PTP. (C1) is useful for manufacturing a medicament for preventing or treating diseases mediated by PTP such as PTP1B. The disease state or condition is chosen from cancer, diabetes, rheumatoid arthritis and hypertension (claimed).

(I) is useful in prophylaxis or treatment of a range of disease states or conditions mediated by PTP, such as obesity, autoimmune diseases, acute and chronic inflammation and osteoporosis.

☐ 5. Document ID: US 20030224335 A1

L2: Entry 5 of 5 File: DWPI Dec 4, 2003

DERWENT-ACC-NO: 2004-167135
DERWENT-WEEK: 200416

TITLE: Crystal useful for determining functional roles of CD45 in immunity, and phosphorylation events comprising CD45 or leukocyte common antigen related molecular structures and diffracting X-rays to a resolution of 5-2 Angstroms

INVENTOR: FREDERICK, C; SAITO, H

PRIORITY-DATA: 2002US-362594P (March 8, 2002), 2003US-0385206 (March 10, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030224335 A1	December 4, 2003		103	G01N033/00

INT-CL (IPC): G01N 33/00; G09B 1/00; G09B 19/02

ABSTRACTED-PUB-NO: US20030224335A
BASIC-ABSTRACT:

NOVELTY - A crystal (I) comprising CD45 (also known as leukocyte common antigen (LCA)) or leukocyte common antigen related (LAR) molecular structures where the crystal effectively diffracts X-rays for the determination of at least one of the structures to a resolution of 5-2 Angstrom or less.

DETAILED DESCRIPTION - A crystal (I) comprises CD45 (also known as leukocyte common antigen (LCA)) or leukocyte common antigen related (LAR) molecular structures where the crystal effectively diffracts X-rays for the determination of at least one of the structures to a resolution of 5-2 Angstrom or less. The crystal may be (a) a crystal (Ia) comprising D1 and D2 protein tyrosine phosphatase (PTPase) domains and effectively diffracts X-rays for the determination of the atomic coordinates to a resolution of at least 3 Angstrom . (Ia) has a space group of P1 with the unit cell dimensions of a=86 Angstrom , b=60 Angstrom , c=161 Angstrom , alpha =90 deg. , beta =100 deg. and gamma =90 deg. , (b) a crystal (Ib) comprising D1 and D2 PTPase domains and effectively diffracts X-rays for the determination of the atomic coordinates to a resolution of 5 Angstrom or greater, and where the crystal has a space group of P2(1) with the unit cell dimensions of a=86 Angstrom , b=59.7 Angstrom , c=160 Angstrom , and beta =99.9 deg. , or (c) a crystal (Ic) comprising D1 and D2 PTPase domains and effectively diffracts X-rays for the determination of the atomic coordinates to a resolution of 5 Angstrom or greater, and where the crystal has a space group of P2(1) with the unit cell dimensions of a=66.92 Angstrom , b=62.73 Angstrom , c=161.59 Angstrom .

INDEPENDENT CLAIMS are also included for the following:

(1) making (M1) crystals involves cloning of CD45 or LAR molecules from cells producing the molecules into suitable expression vectors, and, contacting the expression vectors with suitable host cells, where the host cells express CD45 or LAR gene products, and, purifying the gene products, where the purified gene products are mixed with reservoir solutions, and, growing crystals of the gene products by hanging drop micro vapor diffusion. The crystals effectively diffract X-rays for the determination of the crystal structures to a resolution 5 Angstrom or less and sufficient to determine atomic co-ordinates of the crystals;

(2) a crystal structure, where LAR is co-crystallized with phosphate analogs in the presence of phosphopeptide substrates;

(3) a crystal structure, where CD45 is co-crystallized with phosphate analogs in the presence of phosphopeptide substrates;

(4) a crystal structure of CD45, where the crystal comprises mutated amino terminal and carboxy terminal ends;

(5) identifying molecules that bind to a CD45 molecule involves selecting a potential compound through the use of the set of atomic coordinates corresponding to each of the active sites from the two molecules (LAR and CD45) that comprise (I) asymmetric unit, where the selecting is performed in conjunction with computer modeling, contacting the potential compound with a CD45 molecule or its fragments, and measuring the binding affinity of CD45 molecule or its fragments, and co-crystallizing CD45 molecule or its fragments, where a potential compound is identified when the crystal effectively diffracts X-rays for the determination of the structures to a resolution of 5 Angstrom or greater, sufficient to determine atomic co-ordinates of the crystals; and

(6) obtaining structural information of a molecule involves generating an X-ray diffraction pattern from a crystallized molecule or molecular complex, and applying at least a portion of the structure coordinates to the X-ray diffraction pattern to generate a three-dimensional electron density map of the molecule or molecular complex whose structure is unknown.

USE - (I) is useful for understanding regulation of protein tyrosine phosphorylation and thus about the control of basic cellular process and is essential to understanding the mechanisms of a wide range of diseases such as the generation of cancer as well as diseases resulting from the improper control of the body's defensive and autoimmune responses. (I) is useful in structure-based or rational drug design techniques to design, select, and synthesize chemical entities, including inhibitory compounds that are capable of binding to CD45, LAR, CD45-chimeric protein complexes, LAR-chimeric protein complexes or their portion. The structure coordinates of the crystal complexes and can also be used to and in obtaining structural information about another crystallized molecule or molecular complex. (I) is useful for determining the functional roles of CD45 and LAR in immunity, phosphorylation events, disease initiation mechanism.

ADVANTAGE - The crystal structure provides clear, stable, high quality crystals, visualization of the membrane distal PTPase (D2) domain and the structures of the two consecutive PTPase domains within the same polypeptides chain.

Terms	Documents
(HPTP or protein adj3 tyrosine phosphatase) and crystal and x-ray and atomic coordinates	5

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 20 of 20 returned.

☐ 1. Document ID: US 20060194949 A1

L4: Entry 1 of 20 File: PGPB Aug 31, 2006

PGPUB-DOCUMENT-NUMBER: 20060194949
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060194949 A1

TITLE: Structure of the farnesoid x receptor ligand binding domain and methods of use therefor

PUBLICATION-DATE: August 31, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Downes; Michael R.	San Diego	CA	US
Verdicia; Mark A.	New York	NY	US
Noel; Joseph P.	San Diego	CA	US
Evans; Ronald M.	La Jolla	CA	US
Bowman; Lindsey J.	San Diego	CA	US
Bowman; Marianne	San Diego	CA	US

US-CL-CURRENT: 530/350; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20060173633 A1

L4: Entry 2 of 20 File: PGPB Aug 3, 2006

PGPUB-DOCUMENT-NUMBER: 20060173633
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060173633 A1

TITLE: Crystalline phosphatase and method for use thereof

PUBLICATION-DATE: August 3, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Rupert; Peter Benjamin	Seattle	WA	US

US-CL-CURRENT: 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 3. Document ID: US 20060127397 A1

L4: Entry 3 of 20 File: PGPB Jun 15, 2006

PGPUB-DOCUMENT-NUMBER: 20060127397
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060127397 A1

TITLE: RAG polypeptides, nucleic acids, and their use

PUBLICATION-DATE: June 15, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Strittmatter; Stephen S.	Guilford	CT	US

US-CL-CURRENT: 424/143.1; 514/12, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 4. Document ID: US 20060014180 A1

L4: Entry 4 of 20 File: PGPB Jan 19, 2006

PGPUB-DOCUMENT-NUMBER: 20060014180
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060014180 A1

TITLE: Human phosphatase RET31, and variants thereof

PUBLICATION-DATE: January 19, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Jackson; Donald G.	Lawrenceville	NJ	US
Ramanathan; Chandra S.	Wallingford	CT	US
Feder; John N.	Belle Mead	NJ	US
Mintier; Gabe	Hightstown	NJ	US
Lee; Liana	North Brunswick	NJ	US
Nelson; Thomas C.	Lawrenceville	NJ	US
Siemers; Nathan	Pennington	NJ	US
Bol; David	Langhorne	PA	US
Suchard; Suzanne	Wilmington	DE	US
Schieven; Gary	Lawrenceville	NJ	US
Finger; Joshua	San Marcos	CA	US

Todderrud; C. Gordon	Newtown	PA	US
Bassolino; Donna	Hamilton	NJ	US
Krystek; Stanley	Ringoes	NJ	US
Banas; Dana	Hamilton	NJ	US
McAtee; Patrick	Pennington	NJ	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 5. Document ID: US 20050288217 A1

L4: Entry 5 of 20 File: PGPB Dec 29, 2005

PGPUB-DOCUMENT-NUMBER: 20050288217
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050288217 A1

TITLE: Method for enhancing or inhibiting insulin-like growth factor-I

PUBLICATION-DATE: December 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Clemmons, David R.	Chapel Hill	NC	US
Maile, Laura A.	Chapel Hill	NC	US

US-CL-CURRENT: 514/7; 514/12, 514/13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 6. Document ID: US 20050221459 A1

L4: Entry 6 of 20 File: PGPB Oct 6, 2005

PGPUB-DOCUMENT-NUMBER: 20050221459
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050221459 A1

TITLE: Geranylgeranyl transferase type I (GGTase-I) structure and uses thereof

PUBLICATION-DATE: October 6, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Taylor, Jeffrey S.	Milford	CT	US
Reid, T. Scott	Durham	NC	US
Beese, Lorena S.	Durham	NC	US

US-CL-CURRENT: 435/193; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 7. Document ID: US 20050130286 A1

L4: Entry 7 of 20 File: PGPB Jun 16, 2005

PGPUB-DOCUMENT-NUMBER: 20050130286
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050130286 A1

TITLE: POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES

PUBLICATION-DATE: June 16, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Jackson, Donald G.	Lawrenceville	NJ	US
Ramanathan, Chandra S.	Wallingford	CT	US
Feder, John N.	Belle Mead	NJ	US
Mintier, Gabe	Hightstown	NJ	US
Lee, Liana	North Brunswick	NJ	US
Nelson, Thomas C.	Lawrenceville	NJ	US
Siemers, Nathan	Pennington	NJ	US
Bol, David	Langhorne	PA	US
Suchard, Suzanne	Wilmington	DE	US
Schieven, Gary	Lawrenceville	NJ	US
Finger, Joshua	San Marcos	CA	US
Todderrud, C. Gordon	Newtown	PA	US
Bassolino, Donna	Hamilton	NJ	US
Krystek, Stanley	Ringoes	NJ	US
Banas, Dana	Hamilton	NJ	US
McAtee, Patrick	Pennigton	NJ	US

US-CL-CURRENT: 435/196; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 8. Document ID: US 20050123530 A1

L4: Entry 8 of 20 File: PGPB Jun 9, 2005

PGPUB-DOCUMENT-NUMBER: 20050123530
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050123530 A1

TITLE: Stabilized proteins

PUBLICATION-DATE: June 9, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Marshall, Christopher P.	Brooklyn	NY	US
Hoffman, Alexander	Los Angeles	CA	US
Errico, Joseph P.	Palo Alto	CA	US
Marshall, Paul B.	Munich		DE

US-CL-CURRENT: 424/94.6; 424/178.1, 435/198, 514/12, 530/350, 530/391.1, 530/399, 530/400

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 9. Document ID: US 20050112683 A1

L4: Entry 9 of 20 File: PGPB May 26, 2005

PGPUB-DOCUMENT-NUMBER: 20050112683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050112683 A1

TITLE: Protein sequence analysis apparatus, methods, computer-readable media, computer programs, signals and data structures

PUBLICATION-DATE: May 26, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Reiner, Neil E.	Vancouver		CA
Tcherkassov, Artem	Vancouver		CA
Nandan, Devki	Vancouver		CA

US-CL-CURRENT: 435/7.1; 435/287.2, 436/86, 702/19, 707/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 10. Document ID: US 20050095247 A1

L4: Entry 10 of 20 File: PGPB May 5, 2005

PGPUB-DOCUMENT-NUMBER: 20050095247
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050095247 A1

TITLE: Diagnosis and treatment of infectious diseases through indel-differentiated proteins

PUBLICATION-DATE: May 5, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY

Reiner, Neil E	Vancouver	CA
Tcherkassov, Artem	Vancouver	CA
Nandan, Devki	Vancouver	CA

US-CL-CURRENT: 424/146.1; 530/388.26, 530/391.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 11. Document ID: US 20040171062 A1

L4: Entry 11 of 20 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040171062
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040171062 A1

TITLE: Methods for the design of molecular scaffolds and ligands

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Hirth, Klaus-Peter	San Francisco	CA	US
Milburn, Michael Vance	Emeryville	CA	US

US-CL-CURRENT: 435/7.1; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 12. Document ID: US 20040132634 A1

L4: Entry 12 of 20 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132634
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132634 A1

TITLE: Compositions and methods for regulating the kinase domain of receptor tyrosine kinases

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sicheri, Frank	Toronto		CA
Wybenga-Groot, Leanne	Etobicoke		CA
Pawson, Tony	Toronto		CA

US-CL-CURRENT: 514/1; 435/194, 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 13. Document ID: US 20040077065 A1

L4: Entry 13 of 20 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077065
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077065 A1

TITLE: Three dimensional coordinates of HPTPbeta

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Evdokimov, Artem Gennady	Loveland	OH	US
Pokross, Matthew Eugene	Loveland	OH	US

US-CL-CURRENT: 435/226; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 14. Document ID: US 20040009569 A1

L4: Entry 14 of 20 File: PGPB Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009569
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040009569 A1

TITLE: Kinase crystal structures and materials and methods for kinase activation

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Barford, David	London		GB
Yang, Jing	Middlesex		GB
Hemmings, Brian Arthur	Bettingen		CH
Cron, Peter David	Basel		CH

US-CL-CURRENT: 435/194; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 15. Document ID: US 20040005687 A1

L4: Entry 15 of 20 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005687
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005687 A1

TITLE: Kinase crystal structures

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Barford, David	London		GB
Yang, Jing	Middlesex		GB
Hemmings, Brian Arthur	Bettingen		CH
Cron, Peter David	Basel		CH

US-CL-CURRENT: 435/194; 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 16. Document ID: US 20030224335 A1

L4: Entry 16 of 20 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224335
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224335 A1

TITLE: Receptor linked protein tyrosine phosphatases

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Frederick, Christin	Newton	MA	US
Saito, Haruo	Newton	MA	US

US-CL-CURRENT: 434/193; 436/86

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 17. Document ID: US 20020197628 A1

L4: Entry 17 of 20 File: PGPB Dec 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020197628
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020197628 A1

TITLE: Screening methods for identifying ligands

PUBLICATION-DATE: December 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Stewart, Lansing J.	Bainbridge Island	WA	US

US-CL-CURRENT: 435/6; 435/7.1, 702/19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 18. Document ID: US 20020147146 A1

L4: Entry 18 of 20 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147146
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147146 A1

TITLE: Glycogen synthase kinase-3 inhibitors

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Eldar-Finkelman, Hagit	Shoham		IL

US-CL-CURRENT: 514/12; 435/184

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. D

☐ 19. Document ID: US 20020061549 A1

L4: Entry 19 of 20 File: PGPB May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061549
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061549 A1

TITLE: Stabilized proteins

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Marshall, Christopher P.	Brooklyn	NY	US
Hoffman, Alexander	Los Angeles	CA	US
Errico, Joseph P.	Far Hills	CA	US
Marshall, Paul B.	Munich		DE

US-CL-CURRENT: 435/68.1; 435/198, 530/350, 530/388.1, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 20. Document ID: US 20010034580 A1

L4: Entry 20 of 20 File: PGPB Oct 25, 2001

PGPUB-DOCUMENT-NUMBER: 20010034580
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010034580 A1

TITLE: Methods for using functional site descriptors and predicting protein function

PUBLICATION-DATE: October 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Skolnick, Jeffrey	San Diego	CA	US
Fetrow, Jacquelyn S.	San Diego	CA	US

US-CL-CURRENT: 702/19; 435/7.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(HPTP or protein adj3 tyrosine phosphatase) and crystal and x-ray and atomic coordinates	20

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#